AKTX

Akari Therapeutics PLC

Add to Watchlist

Advanced Chart

1.050

+0.06(6.061%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.090

Open

1.020

VWAP

1.04

Vol

81.31K

Mkt Cap

33.79M

Low

0.999

Amount

84.76K

EV/EBITDA(TTM)

Total Shares

11.74M

31.12M

EV/OCF(TTM)

P/S(TTM)

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

2 Analyst Rating

471.43% Upside

Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

471.43% Upside

Current: 1.050

Low

5.00

Averages

6.00

High

7.00

471.43% Upside

Current: 1.050

Low

5.00

Averages

6.00

High

7.00

Maxim

Jason McCarthy

Buy

initiated

2025-07-18

Reason

Maxim

Jason McCarthy

Price Target

2025-07-18

initiated

Buy

Reason

Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics with a Buy rating and $5 price target.

Maxim

NULL -> Buy

initiated

2025-07-18

Reason

Maxim

Price Target

2025-07-18

initiated

NULL -> Buy

Reason

Maxim initiated coverage of Akari Therapeutics with a Buy rating and $5 price target. The Antibody-Drug Conjugate space is high value at both the commercial and M&A levels, including numerous partnering and licensing deals for preclinical and discovery stage ADC assets, the analyst tells investors in a research note. Combined with challenging biotech markets and broad market headwinds, this story is under-the-radar and just getting started, Maxim argues.

Alliance Global Partners

James Molloy

maintain

$4 -> $7

2025-06-09

Reason

Alliance Global Partners

James Molloy

Price Target

$4 -> $7

2025-06-09

maintain

Reason

Alliance Global Partners analyst James Molloy raised the firm's price target on Akari Therapeutics to $7 from $4 and keeps a Buy rating on the shares. The firm cites its expectations for the company's new antibody drug conjugate centered pipeline following its 2024 merger with Peak Bio for the target increase.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Akari Therapeutics PLC (AKTX.O) is -2.07, compared to its 5-year average forward P/E of 92.93. For a more detailed relative valuation and DCF analysis to assess Akari Therapeutics PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

92.93

Current PE

-2.07

Overvalued PE

361.61

Undervalued PE

-175.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.12

Current PS

0.00

Overvalued PS

4.33

Undervalued PS

-2.09

Financials

Annual

Quarterly

FY2025Q1

YoY :

-41.14%

-3.53M

Operating Profit

FY2025Q1

YoY :

-33.44%

-3.71M

Net Income after Tax

FY2025Q1

0.00

EPS - Diluted

FY2025Q1

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

37.1K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

37.1K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AKTX News & Events

Events Timeline

2025-08-08 (ET)

2025-08-08

07:16:33

Akari Therapeutics sees cash runway into 2028

2025-08-08

07:16:04

Akari Therapeutics reports Q2 EPS (86c) vs. (81c) last year

2025-07-23 (ET)

2025-07-23

08:58:32

Akari Therapeutics reiterates commitment to research on PH1

News

9.0

07-29Newsfilter

Akari Therapeutics Releases Virtual Investor "What This Means" Segment

9.0

06-25Newsfilter

Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent

9.0

06-18Newsfilter

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India